Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease | Zendy

Yuto Yasuda | Zendy; Takashi Nomizo | Zendy; Hiroaki Ozasa | Zendy; Tomoko Funazo | Zendy; Takahiro Tsuji | Zendy; Hironori Yoshida | Zendy; Yuichi Sakamori | Zendy; Hiroki Nagai | Zendy; Tomohiro Handa | Zendy; Takeshi Kubo | Zendy; Young Hak Kim | Zendy

Open Access

Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease

Author(s) -

Yuto Yasuda,

Takashi Nomizo,

Hiroaki Ozasa,

Tomoko Funazo,

Takahiro Tsuji,

Hironori Yoshida,

Yuichi Sakamori,

Hiroki Nagai,

Tomohiro Handa,

Takeshi Kubo,

Young Hak Kim

Publication year - 2017

Publication title -

molecular and clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.442

H-Index - 7

eISSN - 2049-9469

pISSN - 2049-9450

DOI - 10.3892/mco.2017.1373

Subject(s) - medicine , paclitaxel , exacerbation , lung cancer , interstitial lung disease , oncology , cancer , gastroenterology , lung

Lung cancer with preexisting interstitial lung disease (ILD) is difficult to treat due to the risk of acute exacerbation of ILD. Nanoparticle albumin-bound (nab-) paclitaxel improves the overall response rate and reduces neuropathy more efficiently compared with conventional solvent-based (sb-) paclitaxel in patients with advanced non-small-cell lung cancer. However, it is not known whether the risk of acute exacerbation of ILD with nab-paclitaxel is higher compared with that with sb-paclitaxel. Advanced lung cancer patients with ILD treated with nab-paclitaxel (n=14) or sb-paclitaxel (n=14) were retrospectively reviewed. Acute exacerbation of ILD developed in 1/14 patients (7.7%) receiving nab-paclitaxel and 3/14 patients (21.4%) receiving sb-paclitaxel; the difference was not statistically significant. To the best of our knowledge, this is the first study to compare the incidence of acute exacerbation of ILD with nab-paclitaxel with that of sb-paclitaxel in patients with advanced lung cancer with preexisting ILD. The results of the present study support conducting a prospective clinical trial to confirm the clinical benefit of this agent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research